data extraction 2 reviewers independently extracted data from the articles and single manufacturer documents, reconciling differences by consensus. In addition to reviewing published data we asked corresponding authors and independently the manufacturer to provide information regarding the outcomes of inter est and clarification of selected methodo logical details (concealment of randomization, blinded assessment and classification of outcomes, blinding of patients and care-givers, funding source). Final data on outcome measures were obtained from published reports, authors, and in each case sought from manufacturers. Discrepancies were resolved by contacting the study sponsor.
Analysis The data were analyzed using RevMan 5.0 (Cochrane Review Manager, Cochrane Collaboration, Oxford, UK) using the DerSimonian and Laird random effect model. 11 Studies with no events were excluded in all analyses. In each case we analyzed the number of patients with a given outcome allowing only one outcome in a given category per patient. We decided, a priori, to restrict the formal statistical analyses to variables in which 6 or more events occurred. We used a random effects model to pool results from different studies as odds ratio (OR) [95% confidence inter val] (OR <1.0 favors formoterol).
Heterogeneity was explored with the use of methods included in RevMan (I2 and χ2) as well as by performing univariate and multivariable meta -regressions to investigate the following a priori hypotheses of factors potentially influencing effect size: dose of ICS used in the control hospitalization, life threatening exacerbations requiring intubations, and asthma-related death. 5 The above reports, however, included data from clinical settings in which inhaled steroids were not required in all patients. These patients were thus not treated according to current asthma management guidelines which have consistently recommended that LABAs should only be used in combination with inhaled corticosteroids (ICS). 6,7 We have recently published a systematic review and meta-analysis looking specifically at the impact of LABAs (formoterol and salmeterol) on these most serious outcomes in population of patients with mandatory ICS use. 8 Our results suggested that in such patients LABAs did not increase the risk of asthma-related hospitalizations and asthma related serious adverse events. Asthma-related deaths and intubations were too infrequent to establish LABA's relative effect on these outcomes.
In this paper we present data regarding formoterol use alone; data concerning salmeterol were recently published by Bateman et al. 9 Some of the results of this study have been previously reported in an abstract. 10
PATIENTs ANd mEThOds The details of methods were reported in the main manuscript. 8 Key points are presented below.
Eligibility criteria All included studies had the following characteristics: treatment allocation by randomization; para llel control groups (cross-over studies excluded) with at least 12 weeks of treatment; blinding of patients and care-givers; acceptable follow-up of patients receiving study medication (outcome data for the full duration of planned treatment missing for <20% of patients taking formoterol in trials <3 month long, <30% for over 3 months to less than 1 year long, <40% for one year or longer). Eligible studies involved patients with asthma (excluding children younger than 12 years); all patients had to be receiving at least some ICS.
Intervention group Formoterol used regularly twice a day in addition to ICS. Formoterol and ICS could be delivered through single or through separate devices and patients could be receiving ICS as part of study medication or as non-study treatment required by the study protocol.
Control group Eligibility required that all patients in the control group used ICS, either as a part of study protocol (study medication) or as a required background therapy. The dose of ICS need not have been the same in inter vention and control groups. We excluded studies in which control patients received regular LABA or regular short acting β-agonist. We also excluded studies in which the control group, in addition to ICS, received another asthma study medication (leukotriene receptor antagonist, theophylline). received more ICS than patients in the formoterol group; the difference between the groups is thus potentially related to both use of formoterol and to different ICS doses. In TAbLE 4 we present the results of meta-analysis including all 16 studies.
Considering all 16 studies, there were 2 asthma-related deaths (both in formoterol groups, in two separate studies) and no asthma-related non-fatal intubations. One of the deaths occurred in a 35 year old female after an 8 day hospitalization for a severe asthma attack leading to intubation, ventilation, and nosocomial pneumonia with septic shock. The second death occurred in a 65 year old male who developed dyspnea and chest pain and died on admission to hospital despite attempts at cardio-pulmonary resuscitation. There were 8 additional deaths included in the "total mortality" category: 5 in the formoterol-ICS group: 2 categorized as suicide, 1 as pulmonary embolism, 1 as due to malignant metastatic disease and 1 as sudden death. 3 deaths in the ICS group were categorized as due to myocardial infarction, hypertrophic cardiomyopathy, and due to unknown cause respectively. The OR for total mortality was 1.22 (95% CI 0.38-3.90) based on those 7 deaths in formoterol groups and 3 deaths in control groups; with one additional non-fatal intubation in each treatment category the OR for total mortality or intubation was 1.16 (95% CI 0.38-3.57). There were too few events to analyze the relative incidence of most serious asthma-related events-deaths and intubations (2 deaths, both in formoterol groups, and zero asthma-related intubations). The differences between groups in other outcomes included less asthma related hospitalizations (OR 0.59, 95% CI 0.37-0.93) and less asthma-related serious adverse events (heavily influenced by hospitalizations, OR 0.58, 95% CI 0.37-0.91; there were only 5 SAEs which were not hospitalizations) (TAbLE 4, FIGuRE). The trend towards reduction in the incidence of those outcomes was statistically significant in the subgroup of studies using the same dose of ICS in all patients (TAbLE 2, FIGuRE).
Exploration of heterogeneity There was no evidence against the homo geneity or consistency of treatment effects among studies for all outcomes usingα = 0.10 level of significance.
Examination of the a priori hypotheses to explore or explain the residual heterogeneity (similarity of ICS dose in the formoterol and control group, daily dose of formoterol, and the mode of drug delivery investigated, each for several outcomes) revealed no statistically significant impact in all cases.
The results remained unchanged (no change in statistical significance and no important change in OR estimate) when we included 3 studies in which formoterol was administered to all or some patients only once daily Buhl, 2006 Rabe, 2006 . Combining fatal and non-fatal asthma related events (adding deaths to non-fatal hospitalizations and group (similar dose of ICS to formoterol group or increased dose); daily dose of formoterol (9 micrograms per day vs. more); and use of ICS as part of study medications in single device with formoterol, in separate study devices, or as a non-study background medication. These analyses were performed using STATA (version 10.1). In the univariate and multivariable analysis, the criterion for statistical significance for each of the above analyses, performed using a t-test, was set a priori atα = 0.10.
For the estimation of number of patient-years on formoterol treatment we assumed that patients who did not complete the total duration of follow up for a given study received medication assigned by randomization for 50% of the study duration (i.e. for 12 weeks in 24-week studies).
REsuLTs Our analysis included 16 studies identified in course of the process described previously. 8 These publications are listed in Appendix A, the details about included studies are provided in Appendix C of the previous publication. 8 All these studies used concealed randomization procedures, and in all cases assignment of 'asthma-related' to an event was done without knowledge of treatment used. All were sponsored by AstraZeneca. Two studies using formoterol fumarate (Foradil) were sponsored by Novartis or its predecessor (Ciba-Geigy). 12,13 As we have not obtained complete data, those studies are not included in the analyses. However, the authors of primary reports of those studies, while reviewing safety, did not indicate either death or intubation as events in the study. Three additional studies fulfilled all inclusion criteria except that formoterol was administered to at least some patients only once daily Buhl, 2006 Rabe, 2006 Kuna; included in TAbLE 1 and APPENdIx, but not considered in primary analysis). We have examined the impact of those 3 studies on the results using sensitivity analysis (including or excluding them in different combinations) and found no significant effect.
Among included studies 10 used similar doses of ICS in both groups, and six used higher dose of ICS in the control group than in those taking formoterol. For one study we excluded children below 12 years of age (stratified at randomization, study label '2005 O'Byrne'). Together this group of 16 studies included 10,638 participants (5,996 taking formoterol) and provided approximately 4,200 patient-years observation in formoterol groups.
In TAbLE 1 we present the number of events in different outcome categories identified in all 16 studies included in the analysis (and in 3 studies not included). In TAbLE 2 we present the results of meta-analysis of the same events in ten studies in which all patients were on similar dose of ICS, in those studies the difference between the groups are likely related to use of formoterol only. In TAbLE 3 we show results of combined analysis of 6 studies, in which control group patients 
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We favor thus the remaining hypothesis explaining the differences in results -that the prognosis of asthma and the potential effects of LABA in general and formoterol in this case taken regularly are different among patients taking and not taking concomitant inhaled corticosteroid. This hypothesis suggests that ICS provides both protection against severe asthma deterioration and protection against the potential harmful actions of LABA by controlling components of airway inflammation, notably by decreasing airway eosinophil, lymphocyte and mast cell numbers. When LABA is used without concomitant ICS, this inflammatory response may not be adequately controlled, potentially leading to asthma worsening. 14 The main limitations of this study are exclusion of children less than 12 years of age and inability to obtain full data from non AstraZeneca sponsored studies.
In summary, our systematic review evaluated the safety of adding formoterol to ICS and did not reveal convincing evidence of harm. We have extended previous reports that addition of LABA has no detrimental effect on the number of asthma-related hospitalizations and SAEs in patients receiving ICS. 9,15 Due to the very low frequency of most serious events we have not excluded the possibility of a relative increase in deaths in patients receiving formoterol who are also using ICS. We have demonstrated that, in populations similar to those included in the eligible trials, any deleterious effect of formoterol on death or intubations in patients receiving ICS is -if it exists -small in absolute terms. The extent to which our results, taken together with evidence of symptomatic benefits of LABA 16,17 are reassuring regarding the use of formoterol in patients receiving ICS may differ among physicians, patients, and policy-makers.
External funding This study was done without any external funding.
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Roman Jaeschke contributed to all aspects of manuscript development. Paul M. O'Byrne participated in the designing the protocol, obtaining the study data; writing, reviewing and commenting on the manuscript. Filip Mejza, Jan Brożek and Wiktoria Leśniak participated in designing the protocol, searching the literature, selecting articles for inclusion, and reviewing the manuscript. Małgorzata Bała re-run all analyses and confirmed the results. Parameswaran Nair participated in designing the protocol, searching the literature, selecting articles for inclusion, extracting the data, planning the analysis, reviewing the manuscript and providing comments. Lehana Thabane and Ji Cheng participated in designing the protocol, extracting the data (Ji Cheng), non-fatal SAE) also had no important effect on the results. dIsCussION This systematic review and meta--analysis of the effect of formoterol in combination with ICS on serious harmful effects in clinical trials of asthma did not show an increased risk for hospitalizations or serious adverse events; in fact the direction of effect appears beneficial. The relative effect on asthma related mortality and asthma related intubation and ventilation could not be assessed because of the very low number of those events. This contrasts with the report of Nelson et al. related to salmeterol (SMART study) 2 and the subsequent systematic review and the meta-analysis by Salpeter et al. which included both formoterol and salmeterol studies 3 -those authors reported increased risk of deaths and life threatening asthma experiences as well as an increase in the risk of asthma--related hospitalization (OR for hospitalizations in all studies combined 2.6, 95% CI 1.6-4.3, for salmeterol studies OR 1.7, 95% CI 1.1-2.7 and for formoterol studies OR 3.2, 95% CI 1.7-6.0), 3 all in settings in which ICS use was not required in all patients. Similarly, a recent Cochrane review of 62,630 patients in trials comparing salmeterol with placebo or salbutamol in which ICS use was again not mandated in all patients also found an increase in non-fatal serious adverse events related to use of salmeterol against placebo (among over 31,000 adults: OR 1.14, 95% CI 1.01-1.28). 4 Our own analyses, both when looking at combined LABA data 8 and formoterol alone (this paper) did not confirm those findings in a setting mandating use of ICS.
We have discussed potential reasons for this difference in our previous paper. 8 Our conclusions were that the differences were unlikely due to underlying asthma severity, shorter exposure to long acting β-agonist or differences between the randomized trials we examined (phase 3 studies) and the studies suggesting an increased mortality with LABA (post-marketing or phase 4 studies). The possibility that a lack of statistical power to detect a real difference was playing a role -after all both asthma related deaths and majority of all deaths occurred among patients on formoterol -can not be excluded. Our results do not exclude thus a relative increase in asthma related deaths, but show that the absolute increase in formoterol associated deaths or intubations from asthma in populations such as those participating in these trials, if it exists, is small (2 deaths and 0 non-fatal intubations in almost 6,000 patients receiving formoterol during more than 4,000 patient -year observations). Furthermore, in contrast to the Salpeter et al.
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